101 research outputs found
30-Day Postoperative Morbidity of Emergency Surgery for Obstructive Right- and Left-Sided Colon Cancer in Obese Patients: A Multicenter Cohort Study of the French Surgical Association
BACKGROUND: Emergency surgery impairs postoperative outcomes in colorectal cancer patients. No study has assessed the relationship between obesity and postoperative results in this setting.
OBJECTIVE: To compare the results of emergency surgery for obstructive colon cancer (OCC) in an obese patient population with those in overweight and normal weight patient groups.
METHODS: From 2000 to 2015, patients undergoing emergency surgery for OCC in French surgical centers members of the French National Surgical Association were included. Three groups were defined: normal weight (body mass index [BMI] < 25.0 kg/m2), overweight (BMI 25.0-29.9 kg/m2), and obese (BMI ≥30.0 kg/m2).
RESULTS: Of 1,241 patients, 329 (26.5%) were overweight and 143 (11.5%) were obese. Obese patients had significantly higher American society of anesthesiologists score, more cardiovascular comorbidity and more hemodynamic instability at presentation. Overall postoperative mortality and morbidity were 8 and 51%, respectively, with no difference between the 3 groups. For obese patients with left-sided OCC, stoma-related complications were significantly increased (8 vs. 5 vs. 15%, p = 0.02).
CONCLUSION: Compared with lower BMI patients, obese patients with OCC had a more severe presentation at admission but similar surgical management. Obesity did not increase 30-day postoperative morbidity except stoma-related complications for those with left-sided OCC
Venera-D Mission Concept to Study Atmosphere, Surface and Plasma Environment: Phase II Report of the Venera-D Joint Science Definition Team
Venus and Earth were formed approximately the same distance from the Sun, and have almost the same masses and volumes: they should be the most similar pair of planets in the Solar System. A vital, outstanding question is how and when these planets diverged in their atmospheric evolutions. Significantly, recent investigations present evidence for microbial life in Venus' cloud deck. Venus presents us with fundamental questions about the origin and evolution of planetary bodies and life in our Solar System.Venera-D (D stands for the Russian word for "long-lived:" dolgozhivushaya) is a potential mission that would combine simultaneous observations of Venus' atmosphere, plasma environment, and surface to try to answer these essential questions
The ART-XC telescope on board the SRG observatory
ART-XC (Astronomical Roentgen Telescope - X-ray Concentrator) is the hard
X-ray instrument with grazing incidence imaging optics on board the
Spektr-Roentgen-Gamma (SRG) observatory. The SRG observatory is the flagship
astrophysical mission of the Russian Federal Space Program, which was
successively launched into orbit around the second Lagrangian point (L2) of the
Earth-Sun system with a Proton rocket from the Baikonur cosmodrome on 13 July
2019. The ART-XC telescope will provide the first ever true imaging all-sky
survey performed with grazing incidence optics in the 4-30 keV energy band and
will obtain the deepest and sharpest map of the sky in the energy range of 4-12
keV. Observations performed during the early calibration and performance
verification phase as well as during the on-going all-sky survey that started
on 12 Dec. 2019 have demonstrated that the in-flight characteristics of the
ART-XC telescope are very close to expectations based on the results of ground
calibrations. Upon completion of its 4-year all-sky survey, ART-XC is expected
to detect ~5000 sources (~3000 active galactic nuclei, including heavily
obscured ones, several hundred clusters of galaxies, ~1000 cataclysmic
variables and other Galactic sources), and to provide a high-quality map of the
Galactic background emission in the 4-12 keV energy band. ART-XC is also well
suited for discovering transient X-ray sources. In this paper, we describe the
telescope, results of its ground calibrations, major aspects of the mission,
the in-flight performance of ART-XC and first scientific results.Comment: 19 pages, 30 figures, accepted for publication in Astronomy and
Astrophysic
The eROSITA X-ray telescope on SRG
eROSITA (extended ROentgen Survey with an Imaging Telescope Array) is the primary instrument on the Spectrum-Roentgen-Gamma (SRG) mission, which was successfully launched on July 13, 2019, from the Baikonour cosmodrome. After the commissioning of the instrument and a subsequent calibration and performance verification phase, eROSITA started a survey of the entire sky on December 13, 2019. By the end of 2023, eight complete scans of the celestial sphere will have been performed, each lasting six months. At the end of this program, the eROSITA all-sky survey in the soft X-ray band (0.2-2.3 keV) will be about 25 times more sensitive than the ROSAT All-Sky Survey, while in the hard band (2.3-8 keV) it will provide the first ever true imaging survey of the sky. The eROSITA design driving science is the detection of large samples of galaxy clusters up to redshifts z > 1 in order to study the large-scale structure of the universe and test cosmological models including Dark Energy. In addition, eROSITA is expected to yield a sample of a few million AGNs, including obscured objects, revolutionizing our view of the evolution of supermassive black holes. The survey will also provide new insights into a wide range of astrophysical phenomena, including X-ray binaries, active stars, and diffuse emission within the Galaxy. Results from early observations, some of which are presented here, confirm that the performance of the instrument is able to fulfil its scientific promise. With this paper, we aim to give a concise description of the instrument, its performance as measured on ground, its operation in space, and also the first results from in-orbit measurements
Stoma-free survival after anastomotic leak following rectal cancer resection : worldwide cohort of 2470 patients
Funding Information: The TENTACLE-Rectum study was funded by Medtronic External Research Program. The authors declare no other conflict of interest.Peer reviewedPublisher PD
Total Versus Subtotal Gastrectomy for Distal Gastric Poorly Cohesive Carcinoma.
Gastric poorly cohesive carcinoma (PCC) in advanced stages has a poor prognosis. Total gastrectomy (TG) remains the common treatment for distal gastric PCC, but subtotal gastrectomy (SG) may improve quality of life without compromising outcomes. Currently, no clear recommendation on the best surgical strategy for distal PCC is available. This study aimed to compare overall survival (OS) and disease-free survival (DFS) at 5 years for patients with antropyloric PCC treated by total versus subtotal gastrectomy.
A large retrospective European multicenter cohort study analyzed 2131 patients treated for gastric cancer between 2007 and 2017 by members of the French Association of Surgery (AFC). The study compared a group of patients who underwent TG with a group who underwent SG for antropyloric PCC. The primary outcomes were 5 year OS and DFS.
The study enrolled 269 patients: 140 (52.0%) in the TG group and 129 (48.0%) in the SG group. The baseline characteristics and pTNM stage were similar between the two groups. According to Dindo-Claven classification, the patients treated with TG had more postoperative complications than the patients treated with SG (p < 0.001): grades I to IIIa (77.1% vs 59.5%) and grades IIIb to IVb (14.4% vs 9.0%). No difference in 5-year OS was observed between TG (53.8%; 95 % confidence interval [CI], 43.2-63.3%) and SG (53.0%; 95% CI, 41.4-63.3%) (hazard ratio [HR], 0.94; 95% CI, 0.68-1.29). The same was observed for 5-year DFS: TG (46.0%; 95% CI, 35.9-55.5%) versus SG (45.3%; 95% CI, 34.3-55.6%) (HR, 0.97; 95% CI, 0.70-1.34).
At 5 years, SG was not associated with worse OS and DFS than TG for distal PCC. Surgical morbidity was higher after TG. Subtotal gastrectomy is a valuable option for distal PCC gastric cancer
ASO Visual Abstract: Total Versus Subtotal Gastrectomy for Distal Gastric Poorly Cohesive Carcinoma.
- …